Iconic Therapeutics
develops and commercializes biologics-based therapeutics for the treatment of macular degeneration and cancer... Read moreIconic Therapeutics
develops and commercializes biologics-based therapeutics for the treatment of macular degeneration and cancer... Read more
News
Jan 06, 2022
MarketScreener
Iconic Therapeutics: Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor
Dec 02, 2020
Business Wire
Press Release: Iconic Therapeutics : Exelixis In-Licenses Iconic Therapeutics' Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application
Dec 02, 2020
Seeking Alpha
Iconic Therapeutics: Exelixis in-licenses ADC from Iconic Therapeutics, IND filing anticipated soon
Sep 15, 2020
Business Wire
Press Release: Iconic Therapeutics : Exelixis and Iconic Therapeutics Announce Promising Preclinical Data That Support Best-in-Class Potential for ICON-2 in Treatment of Solid Tumors
Aug 22, 2019
BioSpace
Iconic Therapeutics: Iconic Therapeutics Signs Ophthalmology Option Agreement
May 20, 2019
Pharmabiz
Iconic Therapeutics: Exelixis, Iconic ink agreement to advance novel next─generation ADC programme for cancer
May 17, 2019
The Pharma Letter
Iconic Therapeutics: Exelixis continues to look beyond Cabometyx for future growth
May 17, 2019
BioSpace
Iconic Therapeutics: Exelixis and Iconic Therapeutics Enter into Exclusive Option and License Agreement for Novel Antibody-Drug Conjugate Program
Oct 15, 2018
BioPortfolio
Iconic Therapeutics: Iconic Therapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 24072018 Prices from USD $250
Aug 20, 2018
BioPortfolio
Iconic Therapeutics: Iconic Therapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 23042018 Prices from USD $250
Iconic Therapeutics Competitors
1
2
3
4
5
6
7
8
9
10